Vasomotor Menopausal Symptoms (VMS) Treatment Market to Surge USD...

Vasomotor Menopausal Symptoms (VMS) Treatment Market to Surge USD 27.03 billion with Excellent CAGR of 6.20% by 2030

Posted 2024-03-18 12:18:41

105

All of the top players' and brands' company profiles are thoroughly covered in the universal Vasomotor Menopausal Symptoms (VMS) Treatment Market study. The study's projected compound annual growth rate (CAGR) in percentage terms for a given time frame will assist the keyword market industry in making decisions based on future data. The market's consumption and sales are thoroughly examined in this study, which also highlights the leading companies in terms of sales, pricing, revenue, and market share (volume and value) in each region. The extensive Vasomotor Menopausal Symptoms (VMS) Treatment industry study explains the actions of leading companies and competitors in the industry, covering topics such as product launches, acquisitions, mergers, joint ventures, company policies, and popular innovations.

The top-notch Vasomotor Menopausal Symptoms (VMS) Treatment Market research report is the result of skilled abilities and first-rate resources in research, data collection, development, consulting, evaluation, compliance, and regulatory services. Being knowledgeable about the key developments in the Vasomotor Menopausal Symptoms (VMS) Treatment Market sector is essential for success in this cutthroat era, and this can only be achieved with a top-notch market report such as this one. Primary interviews with influential figures, secondary sources, the DBMR market position grid, the DBMR market challenge matrix, and assumptions are all considered in the study approach. The Vasomotor Menopausal Symptoms (VMS) Treatment Market research helps one have a clear understanding of how the industry is changing ahead of their rivals.

Explore Further Details about This Research Vasomotor Menopausal Symptoms (VMS) Treatment Market Report https://www.databridgemarketresearch.com/reports/global-vasomotor-menopausal-symptoms-vms-treatment-market

As per the North American Menopause Society, up to 75% of females in the U.S. witness hot flashes around menopause. Vasomotor symptoms (VMS), including night sweats and hot flashes, are observed in around 68.5% of women as a result of menopause. The median duration of these symptoms is approximately 4 years, though around 10% of women continue to experience VMS as many as 12 years. The increasing incidence of vasomotor and menopausal symptoms such as hot flashes and night sweats among women during menopausal transition is anticipated to boost the market growth.

Data Bridge Market Research analyses a growth rate in the vasomotor menopausal symptoms (VMS) treatment market in the forecast period 2023-2030. The expected CAGR of vasomotor menopausal symptoms (VMS) treatment market is around 6.20% in the mentioned forecast period. The market was valued at USD 16.71 billion in 2022, and it would grow up to USD 27.03 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Vasomotor menopausal symptoms (VMS) are a type of rash which affects the area around the mouth and causes inflammation. The rash will extend up the nose or even into the eyes. The common symptom of this condition is a scaly or red bumpy rash. Lesions on darker skin can be hyperpigmented or brown. Antibiotics can be advantageous for a few weeks, whether oral or topically. Azelaic acid is a prescription-only topical medication. When treatment is disturbed, the problem may reoccur, but the same therapy can be restarted as needed.

Drivers

Increase in Menopause Population

The rise in the number of menopausal women which demands treatment for hot flashes and vaginal dryness globally is one of the primary factors pushing the growth of the vasomotor menopausal symptoms (VMS) treatment market. According to a study published in the International Journal of Applied & Basic Medical Research, about 36.7% of women stated hot flashes among 87.7% of women resulting in menopausal symptoms. As per the North American Menopause Society, around 6,000 women in the U.S. reach menopause every day, and about 2 million women per year. The UN data shows around 985 million women aged 50 years and above in 2020. This number is anticipated to reach 1.65 billion by 2050. Thus,this increasing population will rise the different symptoms of menopause and thus will expand the growth of the market.

Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Scope

The vasomotor menopausal symptoms (VMS) treatment market is segmented on the basis of drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Class

Antidepressants
Fluoxetine
Paroxetine
Sertraline
Hormone Therapy
Anticonvulsant
Phenytoin
Phenobarbital
Others

Route of Administration

Oral
Parenteral
Others

End-Users

Hospitals
Specialty Clinics
Homecare
Others

Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Key players operating in the vasomotor menopausal symptoms (VMS) treatment market include:

Zhejiang Huahai Pharmaceutical Co., Ltd (China)
Teva Pharmaceutical Industries Ltd. (Israel)
Pfizer Inc (U.S.)
Hikma Pharmaceutical PLC (U.K)
Amneal Pharmaceuticals LLC. (U.S.)
Alembic Pharmaceuticals Limited (India)
Zydus Group (India)
Reddy’s Laboratories Ltd (India)
Abbvie, Inc (U.S.)
Sun Pharmaceutical Industries Ltd (India)
Apotex Inc (Canada)
Aurobindo Pharma (India)
Endo Pharmaceuticals plc (Ireland)
Lupin (India)
Novartis AG (Switzerland)
WOCKHARDT (India)

Key questions answered in the Vasomotor Menopausal Symptoms (VMS) Treatment Market are:

What is Vasomotor Menopausal Symptoms (VMS) Treatment Market?
What was the Vasomotor Menopausal Symptoms (VMS) Treatment Market size in 2022?
What are the different segments of the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
What growth strategies are the players considering to increase their presence in Vasomotor Menopausal Symptoms (VMS) Treatment Market?
What are the upcoming industry applications and trends for the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
What are the recent industry trends that can be implemented to generate additional revenue streams for the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
What major challenges could the Vasomotor Menopausal Symptoms (VMS) Treatment Marketface in the future?
What segments are covered in the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
Who are the leading companies and what are their portfolios in Vasomotor Menopausal Symptoms (VMS) Treatment Market?
What segments are covered in the Vasomotor Menopausal Symptoms (VMS) Treatment Market?
Who are the key players in the Vasomotor Menopausal Symptoms (VMS) Treatment Market?